These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2616635)

  • 1. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
    Altamura AC; Mauri MC; De Novellis F; Percudani M; Vampini V
    Pharmacopsychiatry; 1989 Nov; 22(6):246-9. PubMed ID: 2616635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
    Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
    Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.
    Capstick N; Pudney H
    J Int Med Res; 1976; 4(6):435-40. PubMed ID: 800383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics.
    Prosser ES; Csernansky JG; Kaplan J; Thiemann S; Becker TJ; Hollister LE
    J Nerv Ment Dis; 1987 Feb; 175(2):100-5. PubMed ID: 2879880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
    Krakowski M; Czobor P; Volavka J
    Psychiatry Res; 1997 Jun; 71(1):19-26. PubMed ID: 9247978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study.
    Altamura AC; Mauri MC; Mantero M; Brunetti M
    Acta Psychiatr Scand; 1987 Dec; 76(6):702-6. PubMed ID: 3327370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects.
    Torner C; Herrera-Estrella M; Gutiérrez JA; Aguilar-Roblero R
    Int J Neuropsychopharmacol; 2003 Sep; 6(3):243-6. PubMed ID: 12974990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
    Mauri MC; Moliterno D; Rossattini M; Colasanti A
    Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.
    Gerlach J; Rasmussen PT; Hansen L; Kristjansen P
    Acta Psychiatr Scand; 1977 Apr; 55(4):251-60. PubMed ID: 324238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.
    Laux G; Klieser E; Schröder HG; Dittmann V; Unterweger B; Schubert H; König P; Schöny HW; Bunse J; Beckmann H
    Acta Psychiatr Scand Suppl; 1990; 358():125-9. PubMed ID: 1978471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
    Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
    Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
    McEvoy JP; Hogarty GE; Steingard S
    Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
    Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
    Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.